Commission Implementing Regulation (EU) 2023/114 of 16 January 2023 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances benzovindiflupyr, buprofezin, cyflufenamid, fluazinam, flutolanil, lambda-cyhalothrin, mecoprop-P, mepiquat, metiram, metsulfuron-methyl, phosphane and pyraclostrobin (Text with EEA relevance)

• CELEX: Implementing Regulation (EU) 2023/114
• Articles: 3

Article 1

The Annex to Implementing Regulation (EU) No 540/2011 is amended in accordance with the Annex to this Regulation.

Article 2

This Regulation shall enter into force on the third day following that of its publication in the Official Journal of the European Union .

Schedules & Appendices

ANNEX

ANNEX

The Annex to Implementing Regulation (EU) No 540/2011 is amended as follows:

(a)

Part A is amended as follows:

(1)

in the sixth column, expiration of approval, of row 57, Mecoprop-P, the date is replaced by '31 January 2024';

(2)

in the sixth column, expiration of approval, of row 81, Pyraclostrobin, the date is replaced by ‘31 January 2024’;

(3)

in the sixth column, expiration of approval, of row 115, Metiram, the date is replaced by ‘31 January 2024’;

(4)

in the sixth column, expiration of approval, of row 187, Flutolanil, the date is replaced by ‘29 February 2024’;

(5)

in the sixth column, expiration of approval, of row 189, Fluazinam, the date is replaced by ‘29 February 2024’;

(6)

in the sixth column, expiration of approval, of row 191, Mepiquat, the date is replaced by ‘29 February 2024’;

(7)

in the sixth column, expiration of approval, of row 296, Cyflufenamid, the date is replaced by '31 March 2024';

(8)

in the sixth column, expiration of approval, of row 320, Buprofezin, the date is replaced by '31 January 2024';

(b)

Part B is amended as follows: in the sixth column, expiration of approval, of row 28, Phosphane, the date is replaced by '31 March 2024';

(c)

Part E is amended as follows:

(1)

in the sixth column, expiration of approval, of row 3, Metsulfuron-methyl, the date is replaced by '31 March 2024';

(2)

in the sixth column, expiration of approval, of row 4, Benzovindiflupyr, the date is replaced by '2 March 2024';

(3)

in the sixth column, expiration of approval, of row 5, Lambda-Cyhalothrin, the date is replaced by '31 March 2024'.